Get Started Free
Home›Healthcare›Eli Lilly
Eli Lilly logo
Eli Lilly
Healthcare

Eli Lilly Company Overview

Eli Lilly logo

Eli Lilly

● Active
Healthcare · Indianapolis, IN · Est. 1876
PharmaceuticalsBiotechHealthcareGLP-1↗ Website
$740B
Valuation
$60.0B
Revenue
43k+
Employees
1876
Founded

Eli Lilly is a global pharmaceutical company that discovers, develops, and markets medicines across diabetes, oncology, immunology, and neuroscience. Its GLP-1 receptor agonist portfolio — Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity — drove record revenue growth and positioned Lilly as one of the world's most valuable pharmaceutical companies.

Recent Press
5 items
Partnership·2026-02-04
Lilly and U.S. Government Cap Zepbound and Orforglipron at $50/Month for Medicare
Eli Lilly and the U.S. government agreed to cap the cost of Zepbound and the pending oral GLP-1 orforglipron at $50 per month for Medicare beneficiaries beginning April 1, 2026, expanding access for millions of Americans.
Product Launch·2026-02-04
Lilly Oral GLP-1 Orforglipron Nears FDA Approval for Q2 2026 Launch
Eli Lilly's orforglipron, an oral once-daily GLP-1 pill for obesity, is pending FDA approval for an expected Q2 2026 commercial launch, representing a major advance in making weight-loss treatment more convenient and accessible than injectable options.
Press Release·2026-02-04
Lilly Projects $80B-$83B Revenue for 2026 on Zepbound and Mounjaro Surge
Eli Lilly guided 2026 revenues of $80-83 billion, crushing analyst estimates of $77.6 billion, as Zepbound revenue soared 123% to $4.26 billion in Q4 2025 alone, with Mounjaro and Zepbound combined generating $36.5 billion in 2025.
Press Release·2025-10-30
Lilly Raises 2025 Guidance After Q3 Revenue Surge on GLP-1 Boom
Eli Lilly raised its full-year 2025 revenue guidance after Q3 results showed surging Zepbound and Mounjaro demand, with combined GLP-1 product revenue outpacing supply and driving multi-billion dollar manufacturing expansion investments.
Press Release·2025-08-20
Lilly Announces Multi-Billion Dollar Manufacturing Investments in Pennsylvania, Alabama, and Europe
Eli Lilly announced new multi-billion dollar manufacturing facility investments across Pennsylvania, Alabama, and Europe to solve supply chain bottlenecks constraining GLP-1 drug availability for Zepbound and Mounjaro worldwide.
Company History
10 milestones
Colonel Eli Lilly, a Civil War veteran and pharmacist, founded the company in 1876 with a focus on producing quality-controlled medicines — a direct response to the unreliable patent medicines of the era.

Eli Lilly Organization Structure & Team

Org Chart
43,000 employees · Click a leader to explore their team
40,230 across 12 departments
Chief Executive Officer
David A. Ricks
Anat Ashkenazi — Departments
· 40230 people across 12 depts

Eli Lilly Financials, Revenue & Market Share

Annual Revenue
$60.0B
+33% vs prior year
YoY Growth
+33%
From $28.3B to $60.0B
Revenue / Employee
$1.05M
Annual revenue per full-time employee
Revenue Growth
2021
2022
2023
2024
2025
$28.3B
$28.5B
$34.1B
$45.0B
$60.0B
Market Share
GLP-1/Incretin Obesity & Diabetes
38%
share
Eli Lilly
38%
Novo Nordisk
54%
AstraZeneca
4%
Sanofi
2%
Others
2%
$850B
TAM
$220B
SAM
$45.0B
SOM
Revenue Streams
Diabetes44%
Obesity17%
Oncology16%
Immunology11%
Neuroscience7%
Other (Animal Health, Elanco Legacy, Other)5%
Business Units
Cardiometabolic Health61%
Largest segment encompassing diabetes (Mounjaro, Humalog) and obesity (Zepbound) franchises — the primary growth engine with tirzepatide driving the GLP-1 market expansion.
Oncology16%
Portfolio led by Verzenio for breast cancer, which achieved $4.0B in 2024 sales, plus Retevmo, Jaypirca, and Cyramza across targeted therapies.
Immunology & Neuroscience18%
Taltz and Omvoh anchor immunology; Kisunla entered the market in late 2024 for early Alzheimer's disease, representing a new long-term growth driver in neurodegeneration.
Other5%
Legacy branded generics, royalties, and manufacturing service revenue from contract development activities.

Eli Lilly Internal Tools & Processes

Internal Tools
12 departments
Diabetes & Cardiometabolic4800 people · 3 roles
Standards & Certifications
10 standards
Compliance frameworks, security audits, and quality certifications this company maintains.
Regulatory
FDA 21 CFR Part 211
Compliant
Eli Lilly's manufacturing facilities operate under FDA 21 CFR Part 211 Current Good Manufacturing Practice regulations, governing pharmaceutical production, testing, and quality controls for all drug products marketed in the United States, including Mounjaro and Zepbound.
Quality
ICH Q10
Compliant
Lilly applies ICH Q10 Pharmaceutical Quality System guidelines across its global manufacturing network, establishing a lifecycle-based quality framework that supports process understanding, risk management, and continuous improvement for injectable drug products.
Regulatory
GCP (ICH E6 R2)
Compliant
All Lilly clinical trials — including the SURMOUNT obesity trials, SURPASS diabetes program, and TRAILBLAZER-ALZ Alzheimer's studies — are conducted under ICH E6 R2 Good Clinical Practice guidelines to ensure data integrity, patient safety, and regulatory acceptance globally.
Regulatory
EMA GMP
Compliant
Lilly's European manufacturing operations and supply chain comply with EMA Good Manufacturing Practice guidelines, enabling commercial distribution of Mounjaro, Zepbound (as Wegovy equivalent), Verzenio, and other products across EU member states.
Privacy
HIPAA
Compliant
Eli Lilly's LillyDirect patient access platform and clinical data systems comply with HIPAA Privacy and Security Rules, safeguarding protected health information for patients enrolled in savings card programs, home delivery services, and clinical trial registries.
Privacy
GDPR
Compliant
Lilly's European operations and global clinical data systems comply with GDPR requirements for the collection, processing, and transfer of personal health data from EU-resident clinical trial participants, patients, and healthcare professionals.
Environmental
ISO 14001
Certified
Lilly's major manufacturing sites including Indianapolis, Branchburg NJ, and Kinsale Ireland hold ISO 14001 certification for environmental management systems, supporting Lilly's commitment to achieving net-zero greenhouse gas emissions by 2050 across its supply chain.
Safety
ISO 45001
Certified
Lilly's pharmaceutical manufacturing plants and research campuses operate under ISO 45001 occupational health and safety management systems, providing structured hazard identification and risk control for employees handling high-potency active pharmaceutical ingredients.
Regulatory
PhRMA Code on Interactions
Compliant
Lilly adheres to the PhRMA Code governing interactions with healthcare professionals, including restrictions on gifts, meals, and speaker fees — policies enforced through annual training for all commercial and medical affairs employees globally.
Regulatory
Sarbanes-Oxley (SOX)
Compliant
As a NYSE-listed company, Eli Lilly maintains SOX Section 302 and 404 compliance across its financial reporting systems, with annual internal control audits covering its global ERP infrastructure, clinical trial accounting, and revenue recognition processes for drug sales.

Eli Lilly Interview Preparation

Interview Prep
Role-specific interview questions and keywords. Select a department, then click any role to prepare.
Diabetes & Cardiometabolic· 3 roles

Eli Lilly Products & Competitors

Product Suite
5 products · select one to explore
Healthcare
Pharmaceutical
Mounjaro
The first and only GIP and GLP-1 receptor agonist for type 2 diabetes

Mounjaro (tirzepatide) is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adults. In the SURPASS clinical trial program, it demonstrated superior A1c reduction and body weight loss compared to semaglutide, insulin degludec, and other comparators across five pivotal trials.

Use Cases
Titrating type 2 diabetes patients from basal insulin to once-weekly tirzepatide injection to achieve target A1c below 7% with concurrent weight loss benefitInitiating Mounjaro as first injectable therapy in patients failing dual oral therapy (metformin + SGLT2 inhibitor) to avoid insulin escalationUsing Mounjaro in a specialist-managed cardiometabolic clinic to reduce cardiovascular risk factors including HbA1c, body weight, blood pressure, and triglycerides simultaneously
No image
Key Customers
CC
Cleveland Clinic
JDC
Joslin Diabetes Center
MC
Mayo Clinic
Competitive Intelligence
VSOzempic (Novo Nordisk)
THEM

Ozempic (semaglutide 0.5/1/2 mg) is a once-weekly GLP-1 receptor agonist from Novo Nordisk indicated for type 2 diabetes, with the SUSTAIN trial program demonstrating A1c reductions and a cardiovascular outcomes benefit in the SUSTAIN-6 trial.

EDGE

Mounjaro's dual GIP/GLP-1 mechanism delivers significantly greater A1c reduction (up to -2.3% vs -1.8%) and body weight loss (up to -9.5 kg vs -6.2 kg) versus semaglutide 1 mg in head-to-head SURPASS-2 data

VSTrulicity (Eli Lilly predecessor) / Victoza (Novo Nordisk)
THEM

Trulicity (dulaglutide) and Victoza (liraglutide) are once-weekly and once-daily GLP-1 receptor agonists respectively, both established first-generation incretin therapies with long-term safety data and CVOT-validated cardiovascular profiles.

EDGE

Mounjaro's superior glycemic and weight efficacy data from SURPASS trials positions it as the preferred incretin therapy in treatment guidelines for patients with obesity and T2D

VSJardiance + Metformin Combination
THEM

Jardiance (empagliflozin) is an SGLT2 inhibitor from Boehringer Ingelheim/Pfizer with established cardiovascular and renal outcome benefits in T2D, often used as background therapy or alternative to incretin agents in HbA1c management.

EDGE

Mounjaro's injectable mechanism provides substantially greater A1c reduction (2.0–2.3%) versus oral SGLT2 inhibitors (~0.7%), making it the preferred choice when aggressive glycemic control is the primary goal

Related Companies

Agilent Technologies logo
Agilent Technologies
Healthcare
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical analysis, providing instruments, software, services, and consumables for laboratories worldwide. Its customers include pharmaceutical companies, academic research institutions, environmental labs, and food safety organizations that rely on Agilent's measurement science for analysis, testing, and compliance workflows.
Abbott Laboratories logo
Abbott Laboratories
Healthcare
Abbott Laboratories is a global healthcare company that develops and manufactures medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Its portfolio spans the FreeStyle Libre continuous glucose monitoring system — the world's most-used CGM — alongside cardiac devices, point-of-care diagnostics, and infant nutrition brands across 160 countries.
Thermo Fisher Scientific logo
Thermo Fisher Scientific
Healthcare
Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services for scientific research, bioprocessing, clinical diagnostics, and pharmaceutical manufacturing. With over $44B in annual revenue, Thermo Fisher serves pharmaceutical and biotech companies, academic research institutions, clinical laboratories, and government agencies with an unmatched portfolio spanning mass spectrometry, chromatography, cell culture, genetic analysis, and laboratory equipment.
Medtronic logo
Medtronic
Healthcare
Medtronic is the world's largest standalone medical device company, developing therapies and diagnostics across cardiac rhythm management, surgical robotics, neuromodulation, diabetes technology, and endoscopy. Its portfolio spans implantable cardiac monitors, transcatheter pacemakers, robotic surgery platforms, and closed-loop insulin delivery systems used in over 150 countries.
Stryker Corporation logo
Stryker Corporation
Healthcare
Stryker is one of the world's leading medical technology companies, offering a broad portfolio of innovative products and services in orthopedics, medical and surgical equipment, and neurotechnology. The company serves surgeons, hospitals, and healthcare systems across 75 countries with products ranging from joint replacement implants and surgical robots to emergency medical equipment.
Johnson & Johnson logo
Johnson & Johnson
Healthcare
Johnson & Johnson is one of the world's largest healthcare companies, operating across two segments — Innovative Medicine, which develops and markets prescription pharmaceuticals for oncology, immunology, neuroscience, and cardiovascular diseases, and MedTech, which produces surgical robotics, orthopedics, cardiovascular devices, and vision care products. After spinning off its consumer health division as Kenvue in 2023, J&J focuses exclusively on innovative medicine and medical technology.